ANARI-AI
20.4.2021 14:01:13 CEST | Business Wire | Press release
Anari AI , an AI chip factory in the cloud, today announced it has raised $2 million in seed funding led by Earlybird , with participation from Acequia Capital , Serbian Entrepreneurs , and Eric Ries , author and founder of The Lean Startup . The new funding will be used to continue developing the platform and bring it to market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005700/en/
Anari’s platform makes it possible to design personalized AI chips in the cloud with just one click. With this approach, companies are able to build and deploy AI solutions in weeks instead of 12-18 months, and at a fraction of the cost of traditional hardware development.
“AI continues to be growing in size and complexity, and this rate of growth is outpacing standard CPU and GPU performance gains,” said Roland Manger , co-founder and Partner at Earlybird. “Dedicated designs or flexible architectures are expensive, time-consuming and require hardware skills (in short: take lots of effort). Anari is a game changer in two ways: it removes the trade-off between performance and effort, and it makes AI-problem-specific chip solutions available instantaneously in the cloud. I am excited about this huge potential.”
The platform is built on a unique Python-based programming framework—developed by Anari for chip design—that opens up new possibilities for hardware engineers and turns software engineers into hardware designers. The first configurable AI cloud chip from Anari is Thor X, which delivers 100x more efficient processing of 3D Point Cloud/Graph data structures compared to a high-end GPU.
Anari’s team consists of Ph.D. researchers, machine learning experts, and senior software engineers. The team is led by Jovan Stojanovic (co-founder and CEO), Stefan Sredojevic (co-founder and COO), and Bogdan Vukobratovic (co-founder and Head of R&D). Jovan is the founder of the Wonderland AI community that includes more than 30,000 AI experts and enthusiasts from all over the world. The yearly Wonderland AI Summit gathers C-level speakers and attendees from the world’s leading AI companies like NVIDIA, Airbus, HP, IBM, Mercedes, etc.
“You no longer have to tune your model to the computing infrastructure that’s available and designed for broad and generic use cases,” said Sasha Ostojic , ex-VP at NVIDIA, ex-SVP at Cruise Automation, Advisor at Samsung Electronics and Zoox, and Operating Partner at Playground Global.“ Anari's cloud chip technology is the future of cloud computing.”
Roland Manger and Sasha Ostojic will be joining Anari's Board of Directors. Advisors to the company include Christoph Auer-Welsbach (former Partner at IBM Ventures, Founder of CITY AI, and CEO of Kaizo) and Dejan Markovic (co-founder of Flex Logix and Professor at UCLA).
“With AI model complexity doubling every three and a half months, the current way of building the AI infrastructure is not sustainable,” said Jovan Stojanovic, co-founder and CEO of Anari AI. “We believe that every company deserves to have a personalized chip for their AI in just one click. We’re supporting the rapid progress of AI in ways that haven’t been possible until now. With experienced investors like Earlybird on our side, we’re ready to rebuild the AI hardware industry from scratch.”
About Anari AI
Anari AI is rebuilding the AI hardware industry from scratch by delivering a new way of designing and using AI chips through programming in the cloud. The Anari platform for cloud chips can be used by companies across industries such as gaming, automotive and biotechnology to personalize their AI infrastructure with just one click. The company is based in Serbia and has an office in San Francisco. The global team includes advisors with experience from NVIDIA, CERN, IBM, UC Berkeley, and UCLA.
For more information, visit www.anari.ai .
About Earlybird VC
Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets.
Earlybird Venture Capital has grown to three autonomous, dedicated and specialized teams, focusing on digital technologies in Eastern and Western Europe as well as health technologies. Among them, the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. With EUR 1.5 billion under management, seven IPOs and 30 trade sales, Earlybird is one of the most successful venture capital firms in Europe. Discover more at www.earlybird.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005700/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom